Panel Favors Celltrion Biosimilar; Skeptical On Cost Savings
This article was originally published in Scrip
Executive Summary
With the favorable backing by an FDA advisory panel on Feb. 9, which followed a positive review by regulators, Celltrion Inc. and its partner Hospira Inc., a unit of Pfizer Inc., are well on their way of putting the first biosimilar of a monoclonal antibody on the US market.
You may also be interested in...
Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?
With the FDA giving an overwhelmingly positive review of Sandoz Inc.'s application for its biosimilar version of Enbrel (etanercept), which is sold in the US by Amgen Inc., the product appears to be headed to the US market – pending a likely blessing from the agency's advisory panel, which is meeting on July 13. But Sandoz must still get past litigation and convince prescribers and patients its etanercept biosimilar provides value over Enbrel.
Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?
With the FDA giving an overwhelmingly positive review of Sandoz Inc.'s application for its biosimilar version of Enbrel (etanercept), which is sold in the US by Amgen Inc., the product appears to be headed to the US market – pending a likely blessing from the agency's advisory panel, which is meeting on July 13. But Sandoz must still get past litigation and convince prescribers and patients its etanercept biosimilar provides value over Enbrel.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.